Cholinesterase inhibitors for Alzheimer's disease

Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis

“…Four Cochrane reviews have examined cognitive enhancers for AD and found that donepezil, galantamine, and rivastigmine improved cognition, which is consistent with our results. In addition, two of the reviews found that galantamine and rivastigmine improved global status, which is also in agreement with our findings.…”

Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis

“…Four Cochrane reviews have examined cognitive enhancers for AD and found that donepezil, galantamine, and rivastigmine improved cognition, which is consistent with our results. In addition, two of the reviews found that galantamine and rivastigmine improved global status, which is also in agreement with our findings.…”

The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: Interim Results after Two Years of Treatment

“…These findings are consistent with and support previous interim data obtained after one year of observation [17]. After 2 years of treatment, the differences between reference (donepezil) and association (donepezil + choline alphoscerate) were more obvious suggesting that the combined therapy may slow-down the decline in the effectiveness of ChE-I therapies reported after 1-2 years of treatment [10][11][12]. ChE-Is represent the pharmacotherapeutic strategies more extensively used for enhancing cholinergic neurotransmission in AD patients.…”

Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology

“…The reduction of constipation, obstipation, and impaction without exacerbation or emergence of other symptoms in all four patients over an 18 month period suggests that donepezil might be efficacious for treating these symptoms over an extended time frame, including its use for patients simultaneously taking carbidopa-levodopa. The findings are also consistent with previous research demonstrating that donepezil is effective for slowing or reversing cognitive symptom progression in Lewy body disorders, including short-term memory loss, difficulty with word-finding, hallucinations, and cognitive interference [107,[110][111][112][113][114][115][116][117][118][119][120][121][122][123]. To increase our understanding of α-synucleopathology and its role in PD and NCDLB, the symptoms of constipation, obstipation, and impaction, and effective medical interventions, further research is suggested, including longitudinal case studies, as well as large data set analyses using larger numbers of subjects matched for diagnosis, age, gender, and other variables.…”

Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis

“…Four Cochrane reviews have examined cognitive enhancers for AD and found that donepezil, galantamine, and rivastigmine improved cognition, which is consistent with our results. In addition, two of the reviews found that galantamine and rivastigmine improved global status, which is also in agreement with our findings.…”

The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: Interim Results after Two Years of Treatment

“…These findings are consistent with and support previous interim data obtained after one year of observation [17]. After 2 years of treatment, the differences between reference (donepezil) and association (donepezil + choline alphoscerate) were more obvious suggesting that the combined therapy may slow-down the decline in the effectiveness of ChE-I therapies reported after 1-2 years of treatment [10][11][12]. ChE-Is represent the pharmacotherapeutic strategies more extensively used for enhancing cholinergic neurotransmission in AD patients.…”

Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology

“…The reduction of constipation, obstipation, and impaction without exacerbation or emergence of other symptoms in all four patients over an 18 month period suggests that donepezil might be efficacious for treating these symptoms over an extended time frame, including its use for patients simultaneously taking carbidopa-levodopa. The findings are also consistent with previous research demonstrating that donepezil is effective for slowing or reversing cognitive symptom progression in Lewy body disorders, including short-term memory loss, difficulty with word-finding, hallucinations, and cognitive interference [107,[110][111][112][113][114][115][116][117][118][119][120][121][122][123]. To increase our understanding of α-synucleopathology and its role in PD and NCDLB, the symptoms of constipation, obstipation, and impaction, and effective medical interventions, further research is suggested, including longitudinal case studies, as well as large data set analyses using larger numbers of subjects matched for diagnosis, age, gender, and other variables.…”

Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis

“…Four Cochrane reviews have examined cognitive enhancers for AD and found that donepezil, galantamine, and rivastigmine improved cognition, which is consistent with our results. In addition, two of the reviews found that galantamine and rivastigmine improved global status, which is also in agreement with our findings.…”

The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: Interim Results after Two Years of Treatment

“…These findings are consistent with and support previous interim data obtained after one year of observation [17]. After 2 years of treatment, the differences between reference (donepezil) and association (donepezil + choline alphoscerate) were more obvious suggesting that the combined therapy may slow-down the decline in the effectiveness of ChE-I therapies reported after 1-2 years of treatment [10][11][12]. ChE-Is represent the pharmacotherapeutic strategies more extensively used for enhancing cholinergic neurotransmission in AD patients.…”

Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology

“…The reduction of constipation, obstipation, and impaction without exacerbation or emergence of other symptoms in all four patients over an 18 month period suggests that donepezil might be efficacious for treating these symptoms over an extended time frame, including its use for patients simultaneously taking carbidopa-levodopa. The findings are also consistent with previous research demonstrating that donepezil is effective for slowing or reversing cognitive symptom progression in Lewy body disorders, including short-term memory loss, difficulty with word-finding, hallucinations, and cognitive interference [107,[110][111][112][113][114][115][116][117][118][119][120][121][122][123]. To increase our understanding of α-synucleopathology and its role in PD and NCDLB, the symptoms of constipation, obstipation, and impaction, and effective medical interventions, further research is suggested, including longitudinal case studies, as well as large data set analyses using larger numbers of subjects matched for diagnosis, age, gender, and other variables.…”